Early-stage drug discovery in a new-generation ultrahigh-throughput mass spectrometry platform
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2536552123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Nicolás M Morato und 20 weiteren Autor:innen. Beteiligte Einrichtung: Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN 47907. Hauptthemen laut MEDLINE: Drug Discovery, High-Throughput Screening Assays, Spectrometry, Mass, Electrospray Ionization. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Center for Advancing Translational Sciences (NCATS), NCI NIH HHS, HHS | NIH | National Cancer Institute.
Abstract (Originalsprache)
Early-stage drug discovery involves a complex set of processes that typically requires iterative exploration of a vast chemical-biological search space. Over the past few decades, these processes have been facilitated using automated experimentation in the form of high-throughput screening technologies for hit discovery via large-scale biochemical assays of candidate libraries. However, optimized generation of small-molecule candidates is still largely limited to traditional synthetic chemistry workflows, thus representing a bottleneck in the discovery endeavor. Here we describe and demonstrate the capabilities of a next-generation automated ultrahigh-throughput system based on desorption electrospray ionization (DESI) mass spectrometry (MS), which consolidates key activities of early drug discovery: i) organic reaction screening for routes to new candidates, ii) small-scale synthesis following optimized reactions, and iii) bioactivity assessment of the newly generated compounds in a direct-to-biology (i.e., product purification-free) fashion. Importantly, the first two synthetic steps leverage accelerated reactions in microdroplets for on-the-fly synthesis followed by in operando MS analysis or small-scale collection, whereas the later bioanalytical application relies on the label-free nature of MS as well as the contactless and complex-matrix-tolerant nature of DESI. Altogether, this fully automated technology, which has a combined synthetic/analytical throughput of up to ~3 Hz using (sub)nanogram sample amounts (and ca. 6 mHz at the milligram-level synthetic scale), has the potential to accelerate translational efforts via a single-platform closed-loop discovery cycle whose main aspects are illustrated herein, including the demonstration of increases in the biological activity of drug-substance analogs generated in the course of a complete DESI-based direct-to-biology campaign.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN 47907.
- Department of Chemistry, Purdue University, West Lafayette, IN 47907.
- Bindley Bioscience Center, Purdue University, West Lafayette, IN 47907.
- Department of Biochemistry, Purdue University, West Lafayette, IN 47907.
- National Center for Advancing Translational Sciences, Rockville, MD 20850.
- Hamilton Company, Reno, NV 89502.
ORCID-Profile: Nicolás M Morato, Andrew D Mesecar, Julia Balog, R Graham Cooks
Förderung
- HHS | NIH | National Center for Advancing Translational Sciences (NCATS)
- NCI NIH HHS
- HHS | NIH | National Cancer Institute
Zitieren
APA
Morato, N. M., Feng, Y., Chen, K., Huang, K. H., Owen, A., Caruso, J. V., Yang, B., Kulathunga, S. C., Mesecar, A. D., Klumpp-Thomas, C., Radujevic, A., Godfrey, A. G., Gardner, S., Rudnicki, D. D., Galbraith, M., Gloeckner, A., Hajdu, C., Pringle, S. D., Morris, M., …, & Cooks, R. G. (2026). Early-stage drug discovery in a new-generation ultrahigh-throughput mass spectrometry platform. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2536552123
Vancouver
Morato NM, Feng Y, Chen K, Huang KH, Owen A, Caruso JV, et al. Early-stage drug discovery in a new-generation ultrahigh-throughput mass spectrometry platform. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2536552123
BibTeX
@article{Morato2026,
author = {Morato, Nicolás M and Feng, Yunfei and Chen, Kitmin and Huang, Kai-Hung and Owen, Alexis and Caruso, Joseph V and Yang, Beinan and Kulathunga, Samadhi C and Mesecar, Andrew D and Klumpp-Thomas, Carleen and Radujevic, Aco and Godfrey, Alexander G and Gardner, Sean and Rudnicki, Dobrila D and Galbraith, Matt and Gloeckner, Adam and Hajdu, Csaba and Pringle, Steven D and Morris, Michael and Balog, Julia and Cooks, R Graham},
title = {Early-stage drug discovery in a new-generation ultrahigh-throughput mass spectrometry platform},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2536552123}
}
EUVIMED